Press releases
Thursday 24/09/2009 
Pancreatic cancer: researchers find drug that reverses resistance to chemotherapy // 24/09/2009 09.30 h
Dr Davide Melisi (abstract no: 1002)
Session: Basic science/translational research, Thursday 09.00 hrs CEST (Hall 14.2)
Genetic identification of patients who are hypersensitive to radiotherapy helps improve treatment and avoid side-effects // 24/09/2009 10.45 h
Prof Dirk de Ruysscher (abstract no: 2007)
Session: Radiotherapy and Radiobiology, Thursday 10.45 hrs CEST (Hall 15.3)
Could HPV vaccination and screening eradicate cervical cancer?// 24/09/2009 11.15 h
Prof Jack Cuzick
Session: Oncopolicy: Drug and lifestyle mediated prevention initiatives in Europe. Thursday 11.15-12.15 hrs CEST (Hall 3)
New figures on the numbers of new cancers in Europe caused by excess body fat // 24/09/2009 11.15 h
Dr Andrew Renehan (abstract no: 327)
Session: Oncopolicy: Drug and lifestyle mediated prevention initiatives in Europe. Thursday 11.15-12.15 hrs CEST (Hall 3)
Wednesday 23/09/2009
Significant advances made in treatment of malignant melanoma: two trials show improvements in overall survival and rapid shrinking of tumours // 23/09/2009 11.15 h
Steven O’Day (abstract no: 23 LBA) & Paul Chapman (abstract no: 6LBA)
Sessions: O’Day: Melanoma and skin cancer session, Wednesday, 14.45-17.00 hrs CEST (Hall 7); Chapman: Presidential session IV, Thursday, 9.30-11.15 hrs CEST (Hall 1)
New results from SOLTI randomised trial on use of sorafenib in combination with chemotherapy in advanced breast cancer // 23/09/2009 12.30 h
Prof José Baselga (abstract no: 3 LBA)
Session: Presidential III, Wednesday 12.30-14.30 hrs CEST (Hall 1)
New research on ultrasound shows it can predict tumour burden and survival in melanoma patients, sparing unnecessary surgery // 23/09/2009 13.00 h
Dr Christiane Voit (abstract no: 9303)
Session: Melanoma, Wednesday 09.00-10.30 hrs CEST (Hall 7)
Innovative test for new cancer drugs will lead to quicker validation and safer and more efficient clinical trials // 23/09/2009 13.00 h
Dr Ilona Schonn (abstract no: 1013)
Session: Basic Science/Translational Research poster discussion, Wednesday 17.00 – 18.00 hrs CEST (Hall 14.2)
Tuesday 22/09/2009
Case study linked to study on teen and young adult experiences with cancer // 22/09/2009 00.01 h
Jay Wheeler, 17, of Ruislip, Middlesex, UK*
Meta-analysis clarifying the impact of adding cetuximab to various chemotherapy combinations in advanced non-small cell lung cancer // 22/09/2009 00.01 h
Prof Jean-Louis Pujol (abstract no: 9009)
Session: Lung Cancer II, Tuesday 09.00 hrs CEST (Hall 15.2)
Findings of the first study of teen experiences during the process of obtaining a cancer diagnosis // 22/09/2009 00.01 h
Ms Susie Pearce (abstract no: 4170)
Session: Experiences of Care proffered papers, Tuesday 09.00 hrs CEST (Hall 10)
Largest study to date investigates the effect of whole-brain radiotherapy in patients with limited spread of primary cancer to the brain // 22/09/2009 00.01 h
Dr Riccardo Soffietti (abstract no: 8704)
Session: Central Nervous System proffered papers session, Tuesday 09.00 hrs CEST (Hall 7)
Keep taking the medicine: study of adjuvant endocrine treatment for breast cancer reveals the cost of patient non-compliance // 22/09/2009 00.01 h
Prof Cornelis van de Velde (abstract no: 2 BA)
Session: Presidential session, Tuesday 12.30-14.30 hrs CEST (Hall 1)
Switching early breast cancer patients to exemestane improves long-term survival // 22/09/2009 00.01 h
Charles Coombes (abstract 5010)
Session: Breast cancer II – Early disease, Tuesday 09.00-11.00 hrs CEST (Hall 1)
Expert calls for new cancer research priorities and outlines strategy to cope with growing burden of cases// 22/09/2009 09.00 h.
Prof Richard Sullivan
Session: European Partnership for Action Against Cancer, Tuesday 09.00 hrs CEST (Hall 15.3)
Largest and most comprehensive study to date investigates links between prostate cancer hormone therapy and heart disease // 22/09/2009 11.15 h
Ms Mieke Van Hemelrijck (abstract no: 0272)
Session: Presidential, Tuesday 12.15 hrs CEST (Hall 1)
Potentially practice-changing results of phase III trial combining targeted heat therapy with chemotherapy in locally advanced soft tissue sarcoma // 22/09/2009 11.15 h
Prof Rolf Issels (abstract no: 1 LBA)
Session: Presidential II, Tuesday 12.15-14.15 hrs CEST (Hall 1)
Monday 21/09/2009
Die moderne Krebsmedizin arbeitet personalisierter, präziser und schonender zum Wohle des Patienten // 21/09/2009 00.01 h
Hinweis: Dieser Beitrag ist das Thema der deutsch-sprachigen Pressekonferenz unter Vorsitz von Prof. Peter M. Schlag um 11.00 Uhr (MESZ) am Montag, 21. September in Saal 43
New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers // 21/09/2009 00.01 h
J. Louwagie (abstract no: 12 LBA) & U. Stein (abstract no: 13 LBA)
Session: Gastro-intestinal malignancies – colorectal cancer 1, 11-13.15 hrs CEST (Hall 2)
Surgical removal of primary tumour improves survival in metastatic breast cancer patients // 21/09/2009 11. 00h
Dr Jetske Ruiterkamp (abstract no: 5005)
Session: Breast Cancer 1 – advanced disease, Monday 11.00-13.00 hrs CEST (Hall 1)
Can aspirin prevent cancer in people with an inherited predisposition to colon cancer? International clinical trial has the answer // 21/09/2009 11. 00h
Dr John Burn (abstract no: 6000)
Session: Gastro-intestinal malignancies, colorectal cancer session, Monday 11.00 hrs CEST (Hall 2)
New European Academy of Cancer Sciences will help shape future oncology policy // 21/09/2009 13. 00h
Prof Alexander Eggermont
Session: Presidential 1, The unified approach: meeting the cancer challenges in the next decade, Monday 13.15-16.0 hrs CEST (Hall 1)
Page last modified: 23 Sep 2009